Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine + CPX-351 in Newly-Diagnosed AML
NCT04425655Phase 2Terminated
- Sponsor
- University of California, San Diego
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine in acute myeloid leukemia (AML), sponsored by University of California, San Diego. Started Aug 2020; status: terminated.
02
Drugs
fludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04425655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425655.